UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 743

Sortiert nach

2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2859-2862

Vokes, Everett E.

2022

Volltextzugriff (PDF)

HPV-Associated Head and Neck Cancer

JNCI : Journal of the National Cancer Institute, 2015-12, Vol.107 (12), p.djv344-djv344

2015

Volltextzugriff (PDF)

Optimizing Treatment De‐Escalation in Head and Neck Cancer: Current and Future Perspectives

The oncologist (Dayton, Ohio), 2021-01, Vol.26 (1), p.40-48

2021

Volltextzugriff (PDF)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Volltextzugriff (PDF)

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

The New England journal of medicine, 2023-02, Vol.388 (6), p.489-498

2023

Volltextzugriff (PDF)

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

Clinical cancer research, 2015-02, Vol.21 (3), p.632-641

2015

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Volltextzugriff (PDF)

Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology

Nature communications, 2022-11, Vol.13 (1), p.6572-14, Article 6572

2022

Volltextzugriff (PDF)

New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1029-1038

2013

Volltextzugriff (PDF)

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3120-3125

2011

Volltextzugriff (PDF)

Beyond PACIFIC: Uncharted Waters

Journal of thoracic oncology, 2021-05, Vol.16 (5), p.715-718

2021

Volltextzugriff (PDF)

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Clinical cancer research, 2019-09, Vol.25 (17), p.5221-5230

2019

Volltextzugriff (PDF)

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

Clinical cancer research, 2015-02, Vol.21 (4), p.870-881

2015

Volltextzugriff (PDF)

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Journal of clinical oncology, 2008-11, Vol.26 (31), p.5043-5051

2008

Volltextzugriff (PDF)

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-03, Vol.34 (9), p.953-962

2016

Volltextzugriff (PDF)

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

Journal of clinical oncology, 2021-06, Vol.39 (17), p.JCO2100569-1841

2021

Volltextzugriff (PDF)

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Scientific reports, 2021-10, Vol.11 (1), p.20059-20059, Article 20059

2021

Volltextzugriff (PDF)

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2735-2743

2014

Volltextzugriff (PDF)

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

Clinical cancer research, 2015-12, Vol.21 (24), p.5439-5444

2015

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2063-2069

2012

Volltextzugriff (PDF)

1 – 25 von 743

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(698)
Mit Volltextzugriff
(684)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(738)
Japanisch
(105)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(464)
Science & Technology
(462)
Life Sciences & Biomedicine
(454)
Oncology
(399)
Female
(270)
Male
(267)
Middle Aged
(256)
Aged
(246)
Biological And Medical Sciences
(215)
Medical Sciences
(214)
Adult
(209)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(150)
Tumors
(131)
Lung Neoplasms - Drug Therapy
(118)
Combined Modality Therapy
(114)
Aged, 80 And Over
(113)
Chemotherapy
(110)
Head And Neck Neoplasms - Drug Therapy
(109)
Treatment Outcome
(101)
Pharmacology. Drug Treatments
(96)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(175)
Journal Of Thoracic Oncology
(74)
Clinical Cancer Research
(36)
Cancer
(32)
Lung Cancer
(32)
Cancer Research
(25)
Clinical Lung Cancer
(22)
International Journal Of Radiation Oncology, Biology, Physics
(22)
Seminars In Oncology
(18)
Investigational New Drugs
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation

HPV-Associated Head and Neck Cancer

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Optimizing Treatment De‐Escalation in Head and Neck Cancer: Current and Future Perspectives

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology

New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

Beyond PACIFIC: Uncharted Waters

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer

Is This the Dawn of Precision Oncology in Head and Neck Cancer?

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Suchergebnisse filtern